To receive our press releases, please provide your name and contact details below :

13 + 7 =

Advicenne

2, rue Briçonnet, 30 000 Nîmes, France
+33 4 66 05 54 20
investors@advicenne.com

U.S. Investor Relations

Rx Communications Group, LLC
555 Madison Ave,
New York, NY 10022, USA
+001 917-322-2216
Melody Carey mcarey@rxir.com
Paula Schwartz pschwartz@rxir.com

Financial Communications

NewCap
Emmanuel Huynh & Alexia Faure
+33 1 44 71 94 94
advicenne@newcap.eu

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Contact Us

1 + 10 =

© 2019 Advicenne